Response to Autologous HSCT Durable for Patients With Systemic Sclerosis

TUESDAY, Nov. 3, 2026 -- For patients with systemic sclerosis undergoing autologous hematopoietic stem-cell transplantation (HSCT), long-term follow-up indicates durable response, with 60 percent progression-free survival at 10 years, according to a...